Anticonvulsant activity of Erythrina mysorensis bark extract in an animal model of epilepsy
T. S. Nagaraja1★, Riaz Mohamood2, V. Krishna3, B. S. Thippeswamy3, V. P. Veerapur3★ Corresponding author
- 1Department of Pharmaceutics, SJM College of Pharmacy, Chitradurga, India.
- 2Deptartment of Biotechnology & Bioinformatics, Kuvempu University, Shankarghatta, Shimogha, India.
- 3Department of Pharmacology, Siddaganga college of Pharmacy, Tumkur, Karnataka, India.
CORRESPONDENCE
T. S. Nagaraja
Department of Pharmaceutics, SJM College of Pharmacy, Chitradurga, India.
Volume 3, Issue 1 · pp. 62–63 · PUBLISHED 2012 · DOI: 10.4103/0976-500X.92521
View on J Pharmacol. Pharmacother. original site ↗
ABSTRACT
Epilepsy is a common neurological disorder characterized by paroxysmal dysrhythmia, seizure, with or without body convulsions and sensory or psychiatric phenomena. There are many mechanisms by which seizures can develop in either normal or pathologic brains. Three common mechanisms include: (i) diminution of inhibitory mechanism (especially synaptic inhibition due to GABA), (ii) enhancement of the excitatory synaptic mechanism (especially those mediated by NMDA), and (iii) enhancement of endogenous neuronal burst firing (usually by enhancing voltage dependent calcium currents).[1] Erythrina mysorensis is a small tree with few or no prickles.[2] Literature survey reveals that there are no scientific reports regarding anti-epileptic activity of Erythrina mysorensis. Hence this study was undertaken to evaluate anti- epileptic activity of extract of Erythrina mysorensis bark using different in vivo models such as maximum electroshock (MES), pentylenetetrazole, and locomotor activity.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Nagaraja, T. S., Mohamood, R., Krishna, V., Thippeswamy, B. S., & Veerapur, V. P. (2012). Anticonvulsant activity of Erythrina mysorensis bark extract in an animal model of epilepsy. Journal of Pharmacology and Pharmacotherapeutics, 3(1), 62–63. https://doi.org/10.4103/0976-500X.92521
